| scholarly article | Q13442814 |
| P50 | author | Paul Griffin | Q56530199 |
| James S McCarthy | Q64025726 | ||
| P2093 | author name string | Louise Marquart | |
| Peter O'Rourke | |||
| Jörg J Möhrle | |||
| Mark Baker | |||
| Claire Y T Wang | |||
| Silvana Sekuloski | |||
| Suzanne Elliott | |||
| Rebecca Rockett | |||
| Cielo J Pasay | |||
| Christopher Peatey | |||
| P2860 | cites work | Submicroscopic Plasmodium falciparum gametocyte densities frequently result in mosquito infection. | Q44171862 |
| Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria | Q44903369 | ||
| Measurement of Plasmodium falciparum growth rates in vivo: a test of malaria vaccines | Q45037329 | ||
| Increased gametocytemia after treatment: an early parasitological indicator of emerging sulfadoxine-pyrimethamine resistance in falciparum malaria | Q46602096 | ||
| Dihydroartemisinin-piperaquine failure in Cambodia | Q47877123 | ||
| Cytochrome P450 loss-of-function polymorphism genotyping on the Agilent Bioanalyzer and clinical application. | Q51562107 | ||
| Artemisinin Resistance in Plasmodium falciparum Malaria | Q22061852 | ||
| Assessment of the pharmacodynamic properties of antimalarial drugs in vivo | Q24670346 | ||
| Plasmodium falciparum gametocyte carriage in asymptomatic children in western Kenya | Q24798247 | ||
| The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data | Q26822489 | ||
| A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs | Q28476638 | ||
| Inferring developmental stage composition from gene expression in human malaria | Q28536897 | ||
| Higher gametocyte prevalence following failure of treatment of Plasmodium falciparum malaria with sulfadoxine-pyrimethamine and the combination of chloroquine plus sulfadoxine-pyrimethamine: implications for progression of anti-folate resistance | Q30877630 | ||
| Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge | Q33498809 | ||
| Development of antimalarial drugs and their application in China: a historical review | Q33613977 | ||
| Population pharmacokinetic assessment of the effect of food on piperaquine bioavailability in patients with uncomplicated malaria | Q33622892 | ||
| Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval | Q34298973 | ||
| Changes in health workers' malaria diagnosis and treatment practices in Kenya | Q34499550 | ||
| Open-label, single-dose, parallel-group study in healthy volunteers to determine the drug-drug interaction potential between KAE609 (cipargamin) and piperaquine | Q35595618 | ||
| Evaluating the pharmacodynamic effect of antimalarial drugs in clinical trials by quantitative PCR | Q35746272 | ||
| Evaluation of the QT effect of a combination of piperaquine and a novel anti-malarial drug candidate OZ439, for the treatment of uncomplicated malaria | Q36125476 | ||
| Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites | Q36523062 | ||
| Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. | Q36558557 | ||
| Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study | Q36689509 | ||
| Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update | Q36835613 | ||
| The metabolism of primaquine to its active metabolite is dependent on CYP 2D6 | Q36945581 | ||
| Male and female Plasmodium falciparum mature gametocytes show different responses to antimalarial drugs | Q36969808 | ||
| Dihydroartemisinin-piperaquine treatment of multidrug resistant falciparum and vivax malaria in pregnancy | Q37490566 | ||
| Early parasite clearance following artemisinin-based combination therapy among Ugandan children with uncomplicated Plasmodium falciparum malaria | Q37539183 | ||
| Host immunity as a determinant of treatment outcome in Plasmodium falciparum malaria | Q37686622 | ||
| A real-time, quantitative PCR method using hydrolysis probes for the monitoring of Plasmodium falciparum load in experimentally infected human volunteers | Q41832478 | ||
| Gametocytaemia in Senegalese children with uncomplicated falciparum malaria treated with chloroquine, amodiaquine or sulfadoxine + pyrimethamine | Q41918721 | ||
| Gametocytemia and infectivity to mosquitoes of patients with uncomplicated Plasmodium falciparum malaria attacks treated with chloroquine or sulfadoxine plus pyrimethamine. | Q41921699 | ||
| A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains | Q43525538 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Plasmodium falciparum | Q311383 |
| P1104 | number of pages | 9 | |
| P304 | page(s) | 105-113 | |
| P577 | publication date | 2016-04-07 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | Piperaquine Monotherapy of Drug-Susceptible Plasmodium falciparum Infection Results in Rapid Clearance of Parasitemia but Is Followed by the Appearance of Gametocytemia | |
| P478 | volume | 214 |
| Q37254756 | A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study |
| Q47547431 | A controlled human malaria infection model enabling evaluation of transmission-blocking interventions |
| Q50318730 | A randomized feasibility trial comparing four antimalarial drug regimens to induce Plasmodium falciparum gametocytemia in the controlled human malaria infection model |
| Q93107917 | A validation study of microscopy versus quantitative PCR for measuring Plasmodium falciparum parasitemia |
| Q55662003 | Assessing Plasmodium falciparum transmission in mosquito-feeding assays using quantitative PCR. |
| Q40105545 | Concentration of Plasmodium falciparum gametocytes in whole blood samples by magnetic cell sorting enhances parasite infection rates in mosquito feeding assays |
| Q44168331 | Controlled Human Malaria Infection: Applications, Advances and Challenges. |
| Q33880789 | Developing transmission-blocking strategies for malaria control |
| Q57019124 | Development of medicines for the control and elimination of malaria |
| Q37613014 | Estimation of the In Vivo MIC of Cipargamin in Uncomplicated Plasmodium falciparum Malaria |
| Q56378326 | Experimental infection of human volunteers |
| Q37394779 | High prevalence of Plasmodium falciparum gametocyte infections in school-age children using molecular detection: patterns and predictors of risk from a cross-sectional study in southern Malawi |
| Q93253946 | Human Plasmodium vivax mosquito experimental transmission |
| Q33662226 | Initiation of gametocytogenesis at very low parasite density in Plasmodium falciparum infection. |
| Q56355687 | Metabolism of Piperaquine to Its Antiplasmodial Metabolites and Their Pharmacokinetic Profiles in Healthy Volunteers |
| Q83227531 | Modeling the dynamics of gametocytes in humans during malaria infection |
| Q47096821 | Modelling mosquito infection at natural parasite densities identifies drugs targeting EF2, PI4K or ATP4 as key candidates for interrupting malaria transmission |
| Q33709137 | Multiplex, DNase-free one-step reverse transcription PCR for Plasmodium 18S rRNA and spliced gametocyte-specific mRNAs |
| Q28468598 | New developments in anti-malarial target candidate and product profiles |
| Q37149451 | Pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of Actelion-451840 in an induced blood stage malaria study in healthy subjects. |
| Q54255226 | Plasmodium Gametocytes in Field Studies: Do We Measure Commitment to Transmission or Detectability? |
| Q28066456 | Plasmodium vivax Controlled Human Malaria Infection - Progress and Prospects |
| Q33732740 | Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study |
| Q91807410 | Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial |
| Q46852298 | The frontline of controlled human malaria infections: A report from the controlled human infection models Workshop in Leiden University Medical Centre 5 May 2016. |
| Q48005921 | Treating malaria: new drugs for a new era |
| Q54258053 | What goes around comes around: modeling malaria transmission from humans back to mosquitos. |
Search more.